Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Average Recommendation of “Reduce” from Analysts

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have received a consensus rating of “Reduce” from the seven research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and six have issued a hold rating on the company.

Separately, Bank of America upgraded shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research report on Friday, September 6th.

Bayer Aktiengesellschaft Price Performance

Shares of OTCMKTS BAYRY opened at $5.05 on Monday. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.27 and a quick ratio of 0.86. The company’s 50-day moving average price is $6.89 and its 200 day moving average price is $7.25. Bayer Aktiengesellschaft has a 52 week low of $4.94 and a 52 week high of $9.79.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its earnings results on Tuesday, November 12th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.10). The company had revenue of $10.96 billion during the quarter. Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.46%. As a group, sell-side analysts expect that Bayer Aktiengesellschaft will post 1.31 EPS for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.